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Abstract
Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as
monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the
mid-1990s in combination with artesunate. There is a renewed interested in MQ as part of a
triple therapy for the treatment of multi-drug resistance P. falciparum malaria. The wide-
spread use of MQ beyond south-East Asia has been constrained by reports of poor tolerabil-
ity. Here we present the side effect profile of MQ for the treatment of uncomplicated malaria
on the Thai-Myanmar/Cambodia borders. In total 19,850 patients received seven different
regimens containing either 15 or 24–25 mg/kg of MQ, the latter given either as a single
dose, or split over two or three days. The analysis focused on (predominantly) gastrointesti-
nal and neuropsychiatric events as compared to the new fixed dose combination of MQ plus
artesunate given as equal doses of 8 mg/kg MQ per day over three days. Gastrointestinal
side effects were dose-dependent and associated with the severity of malaria symptoms.
Serious neuropsychiatric side effects associated with MQ use were rare: for a single 25 mg/
kg dose it was 11.9 per 10,000 treatments (95% confidence interval, CI, 4–285) vs. 7.8 (3–
15) for the 15 mg/kg dose. The risk with 25 mg/kg was much higher when it was given as
repeat dosing in patients who had failed treatment with 15 mg/kg MQ in the preceding
month; (RR 6.57 (95% CI 1.33 to 32.4), p = 0.0077). MQ was best tolerated as 15 mg/kg or
as 24 mg/kg when given over three days in combination with artesunate. We conclude that
the tolerance of a single dose of MQ in the treatment of uncomplicated malaria is moderate,
but can be improved by administering it as a split dose over three days.
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Introduction
Mefloquine (MQ) is a 4-aminoquinoline-methanol initially developed by the United States
Department of Defense’s Walter Reed Army Institute of Research in the mid-1970s
(WR142,490; [1,2]). It is commercially available from Hoffmann-la-Roche (now Roche Hold-
ing A.G.) since the middle of the 1980s [3–5] (until 2009 in the USA; Lariam1) and is also
widely sold as a generic. MQ was originally deployed as a monotherapy or in the fixed-dose
combination MQ-sulfadoxine-pyrimethamine containing 250mg MQ, 500 mg sulfadoxine
and 50 mg pyrimethamine (MSP, Fansimef1 [6,7]). However to counteract the emergence
and spread of MQ-resistant parasites it was later combined with artesunate, an artemisinin
derivative [8–14] and, since the mid-1990s this combination has been used extensively in
South East Asia and South America.
The widespread deployment and uptake of MQ in other malaria-endemic regions has been
constrained by reports of poor tolerability, particularly with respect to gastrointestinal [15],
neuropsychiatric [16,17] and anecdotally ototoxic [18] adverse side effects. Several reviews
have underlined differences in the prevalence of these adverse effects between various ethnic
groups [19] as well treatment versus prophylactic usage [20].
The gastrointestinal side effects of MQ have been attributed to inhibition of pancreatic β-
cell type-KATP channel Kir6.2/SUR1 [21]. Neuropsychiatric effects cover a spectrum of adverse
events from mild anxiety to serious neurological and psychiatric adverse events, including psy-
chosis, toxic encephalopathy, convulsions and ’acute brain syndrome’ [22]. The exact molecu-
lar mechanism responsible for MQ neurological and psychiatric adverse events is poorly
understood, but inhibition of cholinesterases [23,24], non-receptor tyrosine kinase 2 (Pyk2
[25]) and/or an interaction with adenosine A(2A) receptors [for the (-)-(R,S)-enantiomer in
the MQ racemic mixture [26]] have all been implicated. The roles of the carboxylic acid metab-
olite or the enantiomers with regard to neuropsychiatric toxicity of MQ still need to be more
fully elucidated [27,28]. A study found that the safety and tolerability of a single enantiomer
(+)-MQ was not improved as compared with racemic MQ [29]. That study also reported the
occurrence of dizziness, headaches, nausea and vomiting for various doses of racemic or
(+)-MQ in healthy volunteers. Current estimates of the incidence of MQ serious adverse
events (SAEs) have been derived mostly from retrospective studies and vary from 1 in 100–215
in Europeans to 1 in 1,754 treatments in Asians [13,30–33]. It is unclear whether the serious
adverse reactions to MQ are dose-related [30].
We present here an analysis from prospective clinical trials and retrospectively collated data
of patients with uncomplicated malaria treated with low-dose (15 mg/kg) or standard-dose
MQ (~25 mg/kg), either alone or in combination with artesunate, artemether or sulfadoxine-
pyrimethamine, in regions around the Thai-Myanmar/Cambodia borders (Fig 1). The aim
was to define the risk of gastrointestinal and neuropsychiatric side effects, to explore the asso-
ciation of demographic and clinical factors on tolerability, and to determine if splitting the
dose of MQ over three days decreased the risk of adverse events.
Methods
Our analysis is divided into two parts. The first part reviews the tolerance of MQ in 7,148
patients enrolled in 18 clinical trials and treated with 15 or 25 mg/kg MQ alone or in combina-
tion with artesunate, artemether or sulfadoxine-pyrimethamine, over a 17-year period (1990–
2006) on the Thai-Myanmar border. The second part of the analysis on neuropsychiatric
adverse events includes an additional 12,732 patients with uncomplicated malaria treated with
15 or 25 mg/kg of MQ alone or in combination with artesunate or sulfadoxine-pyrimethamine
from 1989 to 1991 in out-patient clinics along the Thai-Myanmar/Cambodia borders as part
Adverse effects of mefloquine
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of routine patient care by Me´decins Sans Frontières (MSF) and followed by passive case
detection.
Patients and treatments
The clinical studies included in the first analysis were conducted to optimize the treatment of
uncomplicated malaria against the backdrop of increasingly drug-resistant malaria. The
detailed methods of these trials have been published in the respective reports (see Legend to
Fig 1). Briefly, the trials recruited patients with uncomplicated malaria either infected with P.
falciparum alone or co-infected with P. vivax, confirmed by microscopy, provided they or their
guardian gave written informed consent. The exclusion criteria included patients presenting
with signs and symptoms of severe infection, hyperparasitaemia (>4% infected red blood
cells), children and infants weighing less than 5 kg, pregnant women and after 1994, patients
who had been treated with MQ in the preceding two months. MQ was used either as mono-
therapy or in combination with an artemisinin derivative (with the exception of one study
which was in combination with SP; Table 1). Treatment was administered under supervision.
If vomiting occurred within 30 minutes of drug administration the full dose was re-adminis-
tered. Patients who vomited between 30–60 minutes after treatment were re-administered half
the initial dose. No re-treatment was given for vomiting after 60 minutes or later. At each visit,
a blood slide was prepared and each patient was seen daily until parasite-negative, then weekly
for 4–9 weeks. On admission and at each follow-up visit a basic clinical examination was per-
formed, a history of clinical illness taken and a standard side-effects questionnaire completed.
The second analysis to quantify the risk of serious neurological or psychiatric complications
included an additional 12,732 patients with uncomplicated P. falciparum treated at MSF clinics
from 1989 to 1991. Patients from these MSF clinics were not routinely followed-up. Serious
Fig 1. Overview of studies evaluated for neuropsychiatric adverse events. MSF: Me´decins sans
Frontières; SMRU: Shoklo Malaria Research Unit. These studies have been published: [13,14,34–48].
doi:10.1371/journal.pone.0168780.g001
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neurological or psychiatric complications were defined as any event involving the Central Ner-
vous System (CNS) and requiring medical attention. These included acute psychosis, delu-
sions, hallucinations, anxiety neuroses, major disorders of affect, disturbed consciousness, and
seizures. A preliminary analysis of serious neuropsychiatric events observed in the MSF clinics
was published previously [35].
The history of previous antimalarial treatment was documented from the MSF and SMRU
records. For each patient, the presence or absence of behavioral changes was recorded at each
visit. All cases suspected of serious neuropsychiatric reactions by the study nurse or reported
by the family were assessed by a physician at the MSF or SMRU clinics (who were the only pro-
viders of healthcare in the area at the time), or otherwise visited at home by the treating physi-
cian. The number of events and exact denominator were obtained from standardized monthly
malaria treatment records. No details on associated risk factors were available from these
records.
All the studies were approved by the relevant ethics and institutional review committees:
the Faculty of Tropical Medicine Ethical Committee at Mahidol University (Bangkok, Thai-
land) and the Oxford Tropical Research Ethics Committee (OXTREC), University of Oxford,
UK.
Tolerance evaluation: Frequency of adverse events
Gastrointestinal events reported included: vomiting, nausea, anorexia, abdominal pain, and
diarrhea. Neuropsychiatric events included: headache, dizziness, rigors, ataxia, sleep distur-
bances, tremors, and palpitations. All other signs and symptoms were classified as ‘other’. The
patients were assessed for signs and asked about specific symptoms experienced during the last
24 h. Therefore a report on Day1 reflects the occurrence of this event within approximately the
first 24 hours after the start of treatment, a report on Day 2 reflects an occurrence during the
2nd period of 24 hours, etc.
‘Early vomiting’ was defined as vomiting within 1 hour after receiving a dose of MQ, and
‘late vomiting’ as occurring in the subsequent 23 hours. Fever was defined by an axillary tem-
perature >37.5˚C, an oral temperature >38˚C and/or patients reporting fever in the preceding
48 hours.
Table 1. The timing and total dose of MQ (mefloquine) and artesunate from 18 SMRU studies.
Dosing
regimen
MQ dose
(mg/kg)
Combined/
Split
Day of MQ
admin.
Partner
drug
Partner drug
admin.
ART day = 0
(mg/kg)
ART day = 1
(mg/kg)
ART day = 2
(mg/kg)
Total ART
dose (mg/kg)
1 15 Combined D0 SP D0
1 15 Combined D0 - - - -
1 15 Combined D0 ART D0 10 10
2 25 Combined D0 - - - -
2 25 Combined D0 Art/Am D0 (D1/D2) 4 4
3 25 Combined D1 Art D0/D1/D2 4 4 4 12
3 25 Combined D1 - - - -
4 25 Combined D2 Art/Am D0 D1 D2 4 4 4 12
5 25 Split (15/10) D1/D2 ART D0 D1 D2 4 4 4 12
6 25 Split (15/10) D0/D1 - - - -
7 25 Split (8+8+8) D0/D1/D2 ART D0/D1/D2 4 4 4 12
MQ was given combined in a single administration or split in two or three doses; admin.: administration; ART: artesunate; Art/Am: artesunate or artemether;
MQ: mefloquine; SP: sulfadoxine/pyrimethamine.
doi:10.1371/journal.pone.0168780.t001
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Neurological events (psychiatric and others) were documented in the early SMRU trials up
to 2001 inclusive, focusing on the presence of ataxia (Romberg test [49,50], rapid alternate
movements), mobility (tandem walk), fine mobility (picking a tablet), and oculo-vestibular
abnormalities (nystagmus) [15]. However in the absence of any noticeable effects, these events
were not reported in subsequent trials. Data on other neuropsychiatric events, such as tremors,
nightmares or sleep disturbances, impaired hearing and dizziness continued to be collected
throughout the study period.
Statistical analysis
Data were summarized using frequency (n/N, %), geometric means (95% confidence interval
[CI]) or median (inter-quartile range [IQR]), as appropriate. The frequency of early vomiting
was described overall for an individual and also according to episodes, in which case a patient
vomiting on multiple days could be represented more than once. The risk of early vomiting
was calculated by treatment regimen and plotted over the first three days. For dizziness, nau-
sea, late vomiting and anorexia, frequencies were plotted up to day 28. Patients younger than 5
years old were excluded from analyses of dizziness and nausea.
The risk of adverse events was assessed according to the MQ regimen administered, using
as the reference group the new fixed dose combination of MQ plus artesunate, which is given
as equal doses of 8 mg/kg MQ per day over three days (total 24 mg/kg MQ). The six other
MQ-containing dosing regimens included: single 15 mg/kg dose received on day 0, single 25
mg/kg dose received on day 0, single 25 mg/kg dose received on day 1, single 25 mg/kg dose
received on day 2, 25 mg/kg as split dose (15/10), given either as 15 mg/kg on day 0 and 10
mg/kg on day 1, or as 15 mg/kg on day 1 and 10 mg/kg on day 2 (all the latter patients received
artesunate on day 0; Table 1).
The risk rate was calculated as the number of serious adverse events divided by the total
number of patients seen over the same period with exact confidence intervals. Relative risks
and confidence intervals were estimated using Poisson regression with robust error variances
[51]. The median time to resolution of symptoms present at enrolment was calculated by sur-
vival analysis using the Kaplan-Meier method [52], the event being the resolution of the symp-
tom within seven days. Patients with a symptom for whom data were missing were censored
from the last day of a valid observation.
Statistical data analysis was done using STATA, v13 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics of the patients in the clinical trials
For the analysis of MQ tolerance, a total of 7,148 patients were available from 18 SMRU trials
conducted between 1990 and 2006 (Fig 1). In the earlier studies (1990–1992, n = 2,265), 40%
of patients (n = 904) received a single 15 mg base/kg dose. The remaining 6,244 patients were
treated with 24 or 25 mg/kg of MQ (henceforth referred to as 25 mg/kg) administered either as
a single dose (n = 3,212) or as a split dose of 15 mg/kg followed by 10 mg/kg (10+15,
n = 2,305), or three 8-mg/kg doses over three days (8+8+8, n = 727; Table 1).
Patient baseline characteristics at presentation varied significantly over the 16 year study
period (all p< 0.001 for variation by year, data not shown). Overall, the median (IQR) age of
the study participants was 14 years (8–25) years. Nearly two thirds of the participants (60%)
were male and the majority presented with P. falciparum mono-infection at admission (86%,
Table 2).
Adverse effects of mefloquine
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Overview of adverse events
Table 3 lists 26 adverse events that occurred within the first 28 days of follow-up. The most
common neuropsychiatric events on admission were headache (82%), dizziness (47%), and
sleep disturbance (22%). The most common gastrointestinal complaints at admission were
anorexia (62%), nausea (35%), vomiting (23%), and abdominal pain (21%). The frequency of
all of these adverse effects reduced over time, in parallel with the resolution of malaria-associ-
ated symptoms.
Early vomiting
The frequency of early vomiting was highest in young children: 14% (106/735) for children
younger than 5y old, compared to 3.8% (108/2,834) in children aged 5-14y and 2.5% (81/
3,310) in older children and adults (p<0.001). The age-associated patterns in risk of vomiting
were similar across treatment groups (Fig 2 and Table 4). The risk of early vomiting was high-
est on the first days of treatment and with a higher daily MQ dose. The 8+8+8 regimen was
associated with significantly less early vomiting as compared to most other regimens (Fig 3).
This adverse effect of MQ is dose-related and more frequent with a single dose of 25 mg/kg
than with a single dose of 15 mg/kg. The adjusted cumulative risk for patients vomiting any of
their MQ doses over three days showed a similar trend (higher risk with increasing dose of
MQ and in the first days of treatment). The 8+8+8 regimen provided the best tolerability pro-
file, and this remained so after stratifying by year (S1 Table).
Late vomiting, anorexia, nausea and dizziness
The occurrence of symptoms at enrolment was associated with an increased frequency of sub-
sequent side effects (S1 Fig). The frequencies of late vomiting, anorexia, nausea and dizziness
were lower in patients who received the 8+8+8 treatment regimen (S2 Fig). In older children
Table 2. Trial participant baseline characteristics.
Parameter Total Summary statistic
Age in years 7,148 14 (0.24, 95)
Patients younger than 5 years 750 (10.5%)
Aged 5–14 years 2,901 (40.6%)
Aged 15 years and older 3,497 (48.9%)
Male 7,148 4,309 (60.3%)
Geometric mean parasitaemia microl-1 (CI) 7,064 4,179 (3,966–4,403)
Temperature ˚C 6,599 38.1 (1.11)
Fever at presentation* 6,636 5,372 (81.0%)
Baseline HCT % 5,633 36.1 (5.82)
Species at presentation 6,480
P. falciparum 5,547 (85.6%)
P. vivax 1 (0.02%)
Mixed (Pf with Pv) 929 (14.3%)
Mixed (Pf with Po or Pm) 3 (0.05%)
Numbers are mean (SD), Median (min, max) or frequency (%), unless otherwise specified. CI: 95%
confidence interval; HCT: hematocrit; Pf with Po or Pm: Plasmodium falciparum with P. ovale and P.
malariae; SD: standard deviation.
*Defined as temperature >37.5˚C or reported fever in past 48 hours.
doi:10.1371/journal.pone.0168780.t002
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and adults, most symptoms had resolved by Day 28, with the exception of dizziness, which per-
sisted in some patients, particularly in those who had already experienced dizziness upon
admission. The median (IQR) time to resolution of symptoms was 1 or 2 days (1–3 days).
Serious neuropsychiatric adverse events
The risk of serious neuropsychiatric adverse events was assessed in 12,732 patients from the
MSF outpatient clinics and in 7,148 patients from the SMRU trials.
Between 1989 and 1991 at the MSF clinics, there were seven serious neuropsychiatric events
(five on 15 mg/kg MQ and two on 25 mg/kg MQ) reported from a total of 9,468 patients who
received 15 mg/kg of MQ and 3,264 who received M25 treatment, respectively (Table 5).
Detailed of 4 available case reports for these events are presented in S2 Table.
In the SMRU trials, there were a total of eight serious neuropsychiatric adverse events
reported. Six (75%) events occurred in women. Two of these SAEs were documented amongst
345 patients who received 25 mg/kg of MQ within two months of a previous treatment with
MQ, while the remaining 6 SAEs occurred in 6,803 patients who had not received MQ in the
previous two months (RR 6.57 (95% CI 1.33 to 32.4), p = 0.0077). Three of the eight patients
Table 3. Frequency of adverse events.
(Baseline) Day 0 Day 1 Day 2 Day 3 Day 7 Day 28
Adverse event % % % % % %
Gastrointestinal Late vomiting* 1,473/6,462 22.8 976/6,006 16.3 362/5,342 6.78 141/2,532 5.57 54/4,537 1.19 33/3,877 0.85
Nausea 2,099/5,949 35.3 1,641/5,528 29.7 932/4,959 18.8 347/2,331 14.9 166/4,259 3.9 68/3676 1.85
Anorexia 4,006/6,448 62.1 3,490/5,993 58.2 2204/5,339 41.3 853/2,526 33.8 628/4,530 13.9 232/3,873 5.99
Abdominal pain 1,277/6,034 21.2 878/5,607 15.7 522/4,985 10.5 189/2,254 8.39 159/4,213 3.77 97/3,625 2.68
Diarrhea 96/3,105 3.09 113/3,013 3.75 81/2,900 2.79 21/1,269 1.65 26/2,469 1.05 22/2,227 0.99
Neuropsychiatric Headache 4,943/6,033 81.9 3,141/5,585 56.2 1,525/5,000 30.5 561/2,364 23.7 534/4,265 12.5 333/3,654 9.11
Dizziness 2,622/5,549 47.2 2,417/5,154 46.9 1,839/4,638 39.7 868/2,115 41 832/3,963 21 237/3,415 6.94
Rigors 923/4,930 18.7 579/4,583 12.6 260/3,964 6.56 102/1,537 6.64 111/3,244 3.42 88/2,726 3.23
Romberg test 12/1,657 0.72 13/1,224 1.06 8/1,194 0.67 2/152 1.32 3/1,343 0.22 1/1,062 0.09
Tandem walk 16/1,705 0.94 11/1,272 0.86 11/1,241 0.89 5/201 2.49 4/1,345 0.3 2/1,112 0.18
Rapid alt. mvts. 2/499 0.4 1/267 0.37 0/274 0 0/39 0 0/408 0 0/357 0
Pick a tablet 4/1,710 0.23 4/1,276 0.31 2/1,245 0.16 0/201 0 2/1,347 0.15 0/1,113 0
Ataxia 0/50 0 n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e.
Sleep disturb. 567/2,597 21.8 577/2,514 23 477/2,439 19.6 195/1,073 18.2 223/2,101 10.6 39/1,931 2.02
Tremors 32/1,346 2.4 26/1,326 1.96 18/1,307 1.38 10/455 2.2 16/1,160 1.38 3/1,108 0.27
Hearing 91/2,646 3.44 82/2,208 3.71 63/2,164 2.91 28/904 3.1 22/2,151 1.02 10/1,906 0.52
Nystagmus 28/2,025 1.38 19/1,594 1.19 20/1,566 1.28 12/511 2.35 11/1,659 0.66 7/1,426 0.49
Other Rash 63/2,223 2.83 56/2,187 2.56 47/2,156 2.18 17/837 2.03 24/1,878 1.28 16/1,755 0.91
Urticaria 3/893 0.34 2/887 0.23 3/879 0.34 1/430 0.23 1/741 0.13 0/672 0
Fever 5,374/6,639 81 2701/5,502 49.1 735/4,845 15.2 199/2,024 9.83 171/4,040 4.23 180/3,382 5.32
Weakness 2,081/3,433 60.6 1617/3,074 52.6 972/2,587 37.6 510/1,415 36 421/2,232 18.9 153/1,888 8.1
Muscle/joint pain 3,112/5,275 59 1,866/4,937 37.8 901/4,422 20.4 307/1,845 16.6 302/3,694 8.18 211/3,174 6.65
Palpitations 484/2,081 23.3 412/2,064 20 343/2,041 16.8 153/804 19 161/1,772 9.09 36/1,676 2.15
Enlarged spleen 1453/6,288 23.1 n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e.
Enlarged liver 1001/6,295 15.9 n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e.
Fatigue 761/2,181 34.9 647/2,158 30 432/2,127 20.3 122/828 14.7 180/1,843 9.77 69/1,728 3.99
*vomiting occurring at least one hour after MQ administration; n.e.: not evaluated; Rapid alt. mvts.: rapid alternate movements.
doi:10.1371/journal.pone.0168780.t003
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(37.5%) had reported a history of previous neuropsychiatric disorders. While the numbers are
low (7 and 8), there is evidence that overall frequencies in the incidence of EAs at the SMRU
and MSF clinics differ (0.5 vs 1.1/1,000 treatments). If real, this might point to the importance
of passive vs active AE monitoring.
The overall risk of neuropsychiatric events was 7.6/10,000 (95% CI 4 to 12); 7.7/10,000
among patients who received 15 mg/kg and 10.5 to 12/10,000 among patients who received 25
mg/kg MQ (Table 5).
Fig 2. Vomiting frequency (by episode) directly (<1 h) after mefloquine (MQ) administration.
Frequencies are by age group (A-C) and day of treatment.
doi:10.1371/journal.pone.0168780.g002
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Deaths
Three patients died during the follow up period. A 34 year old male with a history of opium
addiction died one month after receiving MQ (15mg/kg) and 3 days of artesunate (2 mg/kg/
d). He had a negative malaria smear by Day 2 and was hospitalized with pneumonia and
cachexia 4 days before death. A 13 year old male died at home on Day 5 after 8+8+8 MQ treat-
ment with an acute surgical abdomen. The third death was a land mine accident in a 15 y old
Table 4. Unadjusted relative risks of any early vomiting (95% CI), by age group.
Age < 5y Age 5–14 y Age >15 y
Regimen Freq. (%) RR (CI) Freq. (%) RR (CI) Freq. (%) RR (CI)
Single 15 mg/kg, d0 19/144 (13.2%) 0.92 (0.37,2.31) 9/360 (2.50%) 0.52 (0.20,1.31) 7/400 (1.75%) 1.72 (0.51,5.82)
Single 25 mg/kg, d0 27/98 (27.6%) 1.39 (0.90,2.15) 34/351 (9.69%) 1.41 (0.97,2.05) 27/501 (5.39%) 2.30 (1.36,3.87)
Single 25 mg/kg, d1 10/41 (24.4%) 1.20 (0.86,1.66) 4/93 (4.30%) 0.96 (0.65,1.42) 2/99 (2.02%) 1.26 (0.72,2.20)
Single 25 mg/kg, d2 28/266 (10.5%) 0.93 (0.74,1.16) 26/1125 (2.31%) 0.83 (0.68,1.01) 8/517 (1.55%) 1.11 (0.82,1.50)
Split 15/10 mg/kg, start d0 12/72 (16.7%) 1.03 (0.85,1.25) 16/189 (8.47%) 1.12 (0.95,1.32) 11/188 (5.85%) 1.42 (1.13,1.78)
Split 15/10 mg/kg, start d1 5/79 (6.33%) 0.87 (0.72,1.06) 11/551 (2.00%) 0.86 (0.74,1.00) 22/1213 (1.81%) 1.1 (0.92,1.31)
3-day 8+8+8 5/35 (14.3%) Ref. 8/165 (4.85%) Ref. 4/392 (1.02%) Ref.
All treatments are compared with the ‘8+8+8’ MQ regimen (8 mg/kg MQ administered on three subsequent days). Early vomiting was defined as vomiting
occurring within one hour of MQ treatment. The unit of analysis was by patient, i.e., if a patient vomited on all three days of treatment with 8+8+8, this was
counted only once. Risks and confidence intervals were estimated using Poisson regression with robust error variances.
doi:10.1371/journal.pone.0168780.t004
Fig 3. Forest plot of adjusted cumulative risk of early vomiting compared with the 8+8+8 treatment group (8 mg/kg MQ on three consecutive
days). Adjusted analyses were stratified by year and included covariates for age, sex, baseline hematocrit, fever at admission, baseline [log] parasitaemia
and vomiting at admission; more specifically to the latter, the occurrence of early vomiting on day 0 for day 1 risk estimates and the occurrence of early
vomiting on day 1 for day 2 risk estimates. Cumulative risks were defined as any vomiting on any day within 1 hour of MQ treatment. The cumulative
frequency for 8+8+8 was 17/593 (for daily frequencies, see S1 Table).
doi:10.1371/journal.pone.0168780.g003
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male on Day 10 after 15 mg/kg MQ. None of these deaths were considered to be related to the
treatment.
Discussion
Our analysis demonstrates that, overall, the main adverse effects of MQ are dose-related and
more frequent with a single dose of 25 mg/kg than with a single dose of 15 mg/kg, as reported
previously. Our analysis also shows that splitting the 25 mg/kg dose over two days reduced this
difference and importantly, when 25 mg/kg was given as 8 mg/kg per day over three consecu-
tive days, the tolerance was similar to that observed with a 15 mg/kg single dose. The frequency
of adverse events was also lower in the group that received artesunate alone on Day 0 and
when MQ treatment commenced as fever and other symptoms abated. The influence of dose
and timing was most apparent in young children (<5 years) and those 5–15 years, although
dizziness was more prevalent and longer-lasting in adults. Overall, the 8+8+8 regimen pro-
vided the best tolerability compared to the other regimens and this was apparent for early
vomiting, nausea and dizziness, although not for late vomiting and anorexia in the youngest
age group.
Neuropsychiatric reactions associated with MQ treatment are more difficult to assess since
such events are rare, even within such a large dataset as the one in the current pooled analysis.
Furthermore malaria itself can be associated with neuropsychiatric complications [53], though
these are mostly seen in cerebral malaria caused by Plasmodium falciparum, and only patients
with uncomplicated malaria were enrolled in this analysis. The neuropsychiatric events were
assessed by a physician at every visit. We only recorded serious adverse event; these were very
obvious and were those spontaneously reported. It is possible that mild events were missed. A
causal relationship for neuropsychiatric reactions was suggested by the strong temporal rela-
tionship with MQ treatment. In all but one patient, these events started within the first few
days after drug administration; in the remaining patient the event occurred on day 27. When
patients were re-treated with 25 mg/kg MQ within one month of initial treatment with 15 mg/
kg the risk of serious events was almost seven-fold higher than with primary 25 mg/kg MQ
treatment. Two of the four patients with serious psychiatric reactions had a history of psychiat-
ric disorders, reinforcing the contraindication of MQ in such patients. However, they also
Table 5. Serious neuropsychiatric events associated with MQ treatment.
Nr. of cases/nr. of patients
Regimen SMRU trials MSF clinicsa Pooled Risk (95% CI) Risk ratio (95% CI)
8+8+8 0/727 - 0/727 -
Single, 15 mg/kg, d0 3/904* 5/9,468 8/10,372 7.71/10,000 (3.33–15.2) Ref.
Single, 25 mg/kg, d0 3/952** 2/3,264 5/4,216 11.9/10,000 (385–27.7) 1.54 (0.50–4.70)
Single, 25 mg/kg, d1 0/350 - 0/350 -
Single, 25 mg/kg, d2 2/1,910† - 2/1,910 10.5/10,000 (1.27–37.8) 1.36 (0.29–6.39)
15/10 mg/kg, start d0 0/453 - 0/453 -
15/10 mg/kg, start d1 0/1,852 - 0/1,852 -
TOTAL 8/7,148 7/12,732 15/19,880 7.55/10,000 (4.22–12.4) -
a Derived with permission from Luxemburger et al., [35], after exclusion of 1,236 patients overlapping with those from the SMRU malaria research trials in
the first column. MSF: Me´decins Sans Frontières
* Two SAEs in this group (1 female, 1 male) occurred after re-treatment with 25 mg/kg MQ for recrudescence.
** Two patients in this group (1 female, 1 male) had a history of major neuropsychiatric disorders.
† One patient in this group (female) had a history of major neuropsychiatric disorders.
doi:10.1371/journal.pone.0168780.t005
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occurred in patients with no prior history, as well as those who had previously tolerated MQ
treatment well.
A limitation of our study is that we only looked at therapeutic use of MQ, in a well-defined
patient cohort. We deliberately chose to analyze the (large) patient cohorts presented in this
study separately from other studies because they are from the same region and were evaluated
using common criteria. One earlier chemoprophylaxis study for MQ reported a 7.9% occur-
rence of AEs among 420 volunteers, but none serious [54]. Older studies had estimated the
risk for neuropsychiatric SAEs at one per 10,600 [55] or one per 13,000 [31], which are about
ten-fold lower than what we report here. Another caveat is that somewhat different inclusion/
exclusion criteria existed for the trials whose results we have combined. However, most of
these (early pregnancy, concomitant use of other medicines) are shared. Among our study’s
strength are the involvement of a relatively homogenous population that is closely followed
medically, and the small number of clinical centers.
The patient population lived in camps for displaced persons on the Thai-Myanmar border,
providing an opportunity to closely monitor rates of serious events. The immediate access to
health care in this relatively confined area and its high utilization facilitated good follow-up.
MSF and the Shoklo Malaria Research Unit (SMRU) were the only suppliers of antimalarials
at the time of these studies within these camps and external drug sources were difficult to
obtain for the displaced persons. We are thus confident that we have an accurate estimate of
the total number of treatments given per period. Although minor, transient changes in behav-
ior and sleep disturbances may go unnoticed in this setting, serious, potentially life-threatening
events, such as acute psychosis, convulsions and impaired consciousness would almost cer-
tainly be brought to the attention of these health services.
The authors are aware of additional clinical studies where the safety of mefloquine was
assessed. Previous studies have attempted to correlate the MQ blood drug concentrations and
the risk of serious [30], or non-serious [15] MQ-related events, but the results have been
inconclusive [47]. We decided against their inclusion for this analysis because of the different
methodologies and populations that were involved.
Of interest is that the tolerance was best in patients treated with the 8+8+8 regimen, which
of all the 25 mg/kg regimens is best absorbed and results in higher drug concentrations of MQ
than achieved with a single dose or split dose of 25 mg/kg. This suggests that peak concentra-
tion per se is not a main determinant of tolerance but that perhaps the rate at which peak con-
centrations are reached is the better predictor of tolerance. The recent WHO malaria
treatment guidelines [56] recommend against the use of MQ within 60 days of a previous
exposure because of the risk of neuropsychiatric toxicity. The increased risk of neuropsychiat-
ric toxicity in enrolled patients re-exposed to a second treatment course within a month also
suggests priming of the CNS, since SAEs were not experienced upon first exposure to MQ.
MQ has extensive tissue distribution [57] and it is not known whether patients with neuropsy-
chiatric reactions have particularly high cerebrospinal concentrations, nor whether clearance
of MQ varies by organ. If clearance from the CNS were particularly slow then patients who
had received MQ previously ( 1 month) might still have a residual CNS concentration. These
data suggest that MQ should not be used as a retreatment drug for MQ failures, also because
little clinical benefit is gained from administration of MQ as second-line treatment of MQ fail-
ures. Our analysis includes data from patients recruited over a 16-year period during which
there were significant variations in the trial designs, baseline characteristics and data acquisi-
tion. Specifically, reporting of adverse events may have differed between younger patients (the
majority cohort seen in the early years) and young adults (more frequently seen in later years).
Nevertheless our analysis sheds light both on the common MQ-associated complications of
gastrointestinal nature and the more serious but less frequent neuropsychiatric symptoms.
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As for many other infectious diseases, the speed at which malaria parasites develop drug
resistance rapidly outpaces the rate at which new medicines are discovered; rather than elimi-
nating the disease there is a very real danger that it will instead make another comeback, as
happened in the second half of the 20th century with the loss of the second generation of anti-
malarials [58]. Resistance against the latest generation of malaria drugs, the artemisinins, is
spreading in southeast Asia [59], and its emergence in Africa could be catastrophic. There is
increasing biological understanding of the costs of resistance to the pathogen. For instance, it
was recently found that resistance against atovaquone results in a failure of the parasite to be
transmitted by mosquitoes [60], and also of resistance incompatibilities. While waiting for
new drugs [61], this suggests strategies whereby ’older’ antimalarials are rotated, or adminis-
tered as two- or three drug regimens (as is routine in other infectious diseases such as HIV/
AIDS and tuberculosis). This in turn requires that we update the safety and efficacy data for
these drugs as more experience is gained from them. The safety of MQ is somewhat controver-
sial yet we feel the drug still has an important role to play in managing disease. A recent study
in African children has confirmed to safety of ASMQ and this will help with the deployment of
this useful combination in Africa [62].
Conclusions
In conclusion, our data confirm earlier findings that gastrointestinal and neuropsychiatric
adverse events following MQ are dose-related, but that 25 mg/kg MQ is much better tolerated
when the total dose is given over three days instead of two days, or as a single dose. We recom-
mend administering MQ as a split dose with strict adherence to the contraindication of MQ in
those with a history of psychiatric illness or re-treatment with MQ within 2 months of prior
MQ therapy as per WHO guidelines. Our analysis highlights the need for the continued moni-
toring of drugs as their use expands, to improve our understanding of adverse effects so that
there their usage can be optimized to maximize tolerability without compromising efficacy.
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